6/25/2025 Categories: Industries Angelini Industries: in 2024 net income up 30% to € 156 million. Group revenues (+3%) and EBITDA (+17%) also on the rise
1/4/2021 Categories: Pharma Angelini Pharma acquires Arvelle Therapeutics to create a leading European innovator in Central Nervous System (CNS) and Mental Health Disorder treatments
9/9/2020 Luxottica and Fameccanica start the national production of face masks at PalaLuxottica in Agordo
7/8/2020 Piero Tansella joins Angelini Holding to coordinate and develop the Group Business Consumer unit
6/16/2020 Categories: Industries Ovid Therapeutics and Angelini Pharma Enter into Exclusive License Agreement to Develop, Manufacture and Commercialize OV101 for the Treatment of Angelman Syndrome in Europe
Angelini Industries
